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Abstract
In vitro screening of 17 Alpine lichen species for their inhibitory activity against 5-lipoxygenase, microsomal
prostaglandin E2 synthase-1 and nuclear factor kappa B revealed Cetrelia monachorum (Zahlbr.) W.L. Culb. & C.F.
Culb. As conceivable source for novel anti-inflammatory compounds. Phytochemical investigation of the ethanolic
crude extract resulted in the isolation and identification of 11 constituents, belonging to depsides and derivatives of
orsellinic acid, olivetolic acid and olivetol. The two depsides imbricaric acid (4) and perlatolic acid (5) approved dual
inhibitory activities on microsomal prostaglandin E2 synthase-1 (IC50 = 1.9 and 0.4 µM, resp.) and on 5-lipoxygenase
tested in a cell-based assay (IC50 = 5.3 and 1.8 µM, resp.) and on purified enzyme (IC50 = 3.5 and 0.4 µM, resp.).
Additionally, these two main constituents quantified in the extract with 15.22% (4) and 9.10% (5) showed significant
inhibition of tumor necrosis factor alpha-induced nuclear factor kappa B activation in luciferase reporter cells with IC50
values of 2.0 and 7.0 µM, respectively. In a murine in vivo model of inflammation, 5 impaired the inflammatory,
thioglycollate-induced recruitment of leukocytes to the peritoneum.
The potent inhibitory effects on the three identified targets attest 4 and 5 a pronounced multi-target anti-
inflammatory profile which warrants further investigation on their pharmacokinetics and in vivo efficacy.
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Introduction
Lichens, wide-spread symbiotic associations between algae/
cyanobacteria and fungi, occur in diverse environmental
conditions, even in very inhospitable climates attended with
extreme temperatures and aridity. Due to the various algal-
fungal-combinations and the variable ecological and climatic
growth conditions, lichens differ widely in appearance and
produce a vast diversity of small chemical entities to protect the
symbiosis partners against environmental influences and
natural enemies. Accordingly, lichens are a rich source of
bioactive secondary metabolites, such as mono- and
diaromatics, terpenoids, steroids, anthraquinones,
naphthoquinones, xanthones, and furans [1], with numerous
reported pharmacological properties, e.g. antibiotic, antifungal,
antiviral, anticancer, antioxidant, anti-inflammatory, analgesic,
and antipyretic [2-6]. Such a variety of activities is also
recognized from Alpine lichen species which remain an
underexplored source for bioactive compounds [7].
Recently, we identified lichen constituents from the chemical
group of depsides and depsidones as potent inhibitors of
microsomal prostaglandin E2 synthase-1 (mPGES-1) using
pharmacophore-based virtual screening tools [8]. Among the
three isoforms of prostaglandin E2 synthases, mPGES-1, an
inflammation induced-, membrane associated-enzyme, has
been described as promising druggable target catalyzing the
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conversion of cyclooxygenase-derived prostaglandin (PG)H2 to
PGE2, primarily affecting pathogenic processes [9].
These previous findings prompted us to further identify
bioactive lichen constituents and to explore their anti-
inflammatory potential. For this purpose diverse Alpine lichen
species were collected and investigated to complement the
previously performed structure-based approach applying an in
vitro screening on mPGES-1. Additionally, we aimed to
investigate the multi-targeting anti-inflammatory potential of
lichen constituents in vitro, which is by far not fully investigated.
Hence, the in vitro screening was extended to a further target
within eicosanoid biosynthesis, namely 5-lipoxygenase (5-LO),
since a dual inhibition of mPGES-1 and 5-LO is reported to
provide safer and more effective anti-inflammatory properties
[10,11]. Moreover, we also examined the lichen extracts for
their inhibitory potential regarding the nuclear factor kappa B
(NF-κB) pathway to broaden our insight into the bioactivity
profile of lichen constituents as anti-inflammatory agents.
Based on the in vitro screening against the focused
pharmacological targets followed by an in depth phytochemical
analysis of the most promising lichen extract (C. monachorum),
we identified two depsides (4 and 5) contributing to the multi-
target in vitro effect. First results from an in vivo pilot study
underpin the anti-inflammatory efficacy of this compound class.
Materials and Methods
Plant material
Lichen material of Cetrelia monachorum (Zahlbr.) W.L. Culb.
& C.F. Culb. was collected from maple bark in Grünau/Almtal,
Upper Austria (47° 44.3’ N and 13° 56.82’ E) in July 2011. The
lichen material was morphologically and microchemically
identified according to Obermayer and Mayrhofer [12].
Further 16 Alpine lichens were collected between August
2010 and August 2011 in Halltal and Ötztal, Tyrol, Austria, and
in Vinschgau, South Tyrol, Italy, and identified according to the
key in Wirth [13]. This included microscopic analyses and
microchemical staining reactions using sodium hypochlorite,
potassium hydroxide and para-phenylendiamine and enabled
the unambiguous assignment of species. Voucher specimens
are deposited at the Institute of Pharmacy/Pharmacognosy,
University of Innsbruck, Austria. Collected lichen species, date,
locality of collection, voucher numbers, amount of dried thalli
and extract yield, are listed in Table S1 in Information S1.
General experimental procedures
All reagents were of purissimum or analytical quality and
purchased from Merck (Darmstadt, Germany) unless otherwise
specified.
Analysis of the metabolite profile of the ethanol crude extract
of C. monachorum (CM) was assessed using the HPLC
method: 1100 Agilent system (Agilent, Waldbronn, Germany)
equipped with photodiode array detector and auto sampler;
stationary phase: Phenomenex Synergi Polar-RP 80A column
(4.6 × 150 mm; 4 µm particle size); mobile phase: aqueous
0.05 % formic acid (A) and MeOH (B); flow rate: 1.0 mL/min;
oven temperature: 35 °C; detection wavelength: 235 nm;
composition: start 10% B; 4 min 20% B; 9 min 60% B; 15 min
63% B; 30 min 63% B; 33 min 74% B; 48 min 75% B; 53 min
98% B; post time 10 min; fitted to MS-parameters: Bruker
Esquire 3000plus iontrap (Bruker Daltonics, Bremen, Germany);
split: 1:5; ESI, alternating mode; spray voltage: 4.5 kV, 350 °C;
dry gas: N2, 10 L/min; nebulizer: He, 40 psi; scanning range:
m/z 100-1500.
NMR: 1D- and 2D-experiments were measured at a Bruker
UltraShield 600 (Bruker Biospin, Rheinstetten, Germany) using
methanol-d4 (1, 2, 4, 5, 6, 8, 9) or CDCl3 (3, 7, 10, 11) as NMR-
solvents (Euriso-Top, Saint-Aubin, France).
Extraction and isolation
For in vitro screening of selected Alpine lichen species the
air-dried thalli were ground with a ball mill (Micro-Dismembrator
U, Sartorius AG) and extracted three times using EtOH 96% at
room temperature and an ultrasonic bath (1 x 10 mL/1 g lichen
material, 2 x 5 mL/1 g lichen material, 1 h each).
For phytochemical investigation of C. monachorum 13 g
dried and ground thalli were extracted at room temperature
with EtOH 96% using an ultrasonic bath (1 x 130 mL, 7 x 80
mL, 1 h each). Upon evaporation to dryness the crude extract
(CM) yielded 1.68 g. Pure compounds 1 - 11 were isolated
according to the schematic flow chart (Figure 1) using column
chromatographic techniques (a detailed description is given in
the online Supporting Information).
Purity of the isolates was determined by HPLC and found to
be ≥95%.
Quantification
To determine the contents of 4 and 5 in CM, standard
solutions of the isolates were diluted in appropriate
concentrations. CM was dissolved in MeOH and insoluble
cloudiness was filtered off. Every sample was measured three
times by HPLC. Data were obtained on Shimadzu (Kyoto,
Japan) UFLC-XR instrument, equipped with on-line degasser,
auto sampler, column thermostat, and photodiode array
detector using the HPLC protocol described above. The
amounts of 4 and 5 were calculated as the percentage of dry
weight of CM. Limits of quantification were determined as the
signal-to-noise ratio of 10.
Preparation of crude mPGES-1 in microsomes of A549
cells and determination of PGE2 synthase activity
Preparations of human A549 cells and determination of
mPGES-1 activity was performed as described previously [10].
In brief, cells were treated with 1 ng/mL interleukin-1β (IL-1β)
for 48 h at 37 °C, 5% CO2. Cells were harvested, sonicated and
the homogenate was subjected to differential centrifugation at
10,000×g for 10 min and 174,000×g for 1 h at 4 °C. The pellet
(microsomal fraction) was resuspended in 1 ml homogenization
buffer (0.1 M potassium phosphate buffer, pH 7.4, 1 mM
phenylmethanesulfonyl fluoride, 60 µg/mL soybean trypsin
inhibitor, 1 µg/mL leupeptin, 2.5 mM glutathione, and 250 mM
sucrose), and the total protein concentration was determined.
Microsomal membranes were diluted in potassium phosphate
buffer (0.1 M, pH 7.4) containing 2.5 mM glutathione. Test
compounds or vehicle (0.1% DMSO) were added, and after 15
min at 4 °C reaction (100 µl total volume) was initiated by
Anti-Inflammatory Depsides from C. monachorum
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addition of PGH2 at the indicated concentrations. After 1 min at
4 °C, the reaction was terminated using stop solution (100 µl;
40 mM FeCl2, 80 mM citric acid, and 10 µM 11β-PGE2 as
internal standard). PGE2 was separated by solid-phase
extraction and analyzed by RP-HPLC as described previously
[10].
Expression and purification of human recombinant 5-
LO and determination of 5-LO activity
E. coli (BL21) was transformed with pT3-5-LO plasmid, and
recombinant 5-LO protein was expressed at 30°C as described
[14]. Cells were lysed in 50 mM triethanolamine/HCl pH 8.0, 5
mM EDTA, soybean trypsin inhibitor (60 µg/mL), 1 mM
phenylmethanesulphonyl fluoride, and lysozyme (1 mg/mL),
homogenized by sonication (3 × 15 sec), and centrifuged at
40,000×g for 20 min at 4°C. The 40,000×g supernatant (S40)
was applied to an ATP-agarose column to partially purify 5-LO
as described previously [14]. Semi-purified 5-LO was
immediately used for activity assays. Thus, aliquots of the
semi-purified enzyme were diluted with ice-cold PBS containing
1 mM EDTA, and 1 mM ATP was added. Samples were pre-
incubated with the test compounds or vehicle (0.1% DMSO) as
indicated. After 10 min at 4°C, samples were pre-warmed for
30 sec at 37°C, and 2 mM CaCl2 plus the indicated
concentrations of arachidonic acid (AA) were added to start 5-
LO product formation. The reaction was stopped after 10 min at
37°C by addition of 1 mL ice-cold methanol, and the formed
metabolites were analysed by RP-HPLC as described [14]. 5-
LO products include the all-trans isomers of leukotriene B4
(LTB4) and 5(S)-hydro(pero)xy-6-trans-8,11,14-cis-
eicosatetraenoic acid (5-H(P)ETE).
Determination of 5-LO products in the cell-based assay
For isolation of polymorphonuclear leukocytes (PMNL),
human peripheral blood (University Hospital Jena, Germany)
was withdrawn from fasted (12 h) healthy donors that had not
taken any anti-inflammatory drugs during the last 10 days, by
venipuncture in heparinized tubes (16 IE heparin/mL blood).
The blood was centrifuged at 4,000×g for 20 min at 20°C for
preparation of leukocyte concentrates. Leukocyte concentrates
were subjected to dextran sedimentation and centrifugation on
LSM 1077 cushions (PAA Laboratories, Linz, Austria).
Contaminating erythrocytes of pelleted PMNL were lysed by
hypotonic lysis. PMNL were washed twice in ice-cold PBS and
finally resuspended in PBS pH 7.4 containing 1 mg/mL glucose
and 1 mM CaCl2 (PGC buffer) (purity > 96-97%).
For determination of LO products in intact PMNL (5 × 106),
cells were resuspended in 1 mL PGC buffer, preincubated for
15 min at 37°C with test compounds or vehicle (0.1% DMSO),
and incubated for 10 min at 37°C with the indicated stimuli.
Thus, the Ca2+-ionophore A23187 (2.5 µM) was added together
with 20 µM AA and 10 min later the reaction was stopped on
ice by addition of 1 mL of ice-cold methanol. Then, 30 µL 1 N
HCL and 500 µL PBS, and 200 ng prostaglandin B1 were
added and the samples were subjected to solid phase
extraction on C18-columns (100 mg, UCT, Bristol, PA, USA). 5-
LO products (LTB4 and its trans-isomers and 5-H(P)ETE) were
analyzed by RP-HPLC and quantities calculated on the basis of
the internal standard PGB1. Cysteinyl-LTsC4, D4 and E4 were
not detected (amounts were below detection limit), and
oxidation products of LTB4 were not determined.
NF-κB transactivation activity and cell viability
The transactivation of a NF-κB-driven luciferase reporter
gene was quantified in HEK-293/NF-κB-luc cells (Panomics,
RC0014) as previously described [15]. Cells stably transfected
Figure 1.  Schematic flow-chart of extraction and isolation (pure compounds encircled).  
doi: 10.1371/journal.pone.0076929.g001
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with a NF-κB luciferase reporter were seeded in 10 cm dishes
and transfected with 5 µg plasmid encoding enhanced green
fluorescent protein (pEGFP-C1; Clontech, Mountain View, CA,
USA). Six hours later cells were seeded in 96-well plates and
incubated at 37°C and 5% CO2 overnight. On the next day, the
medium was exchanged with serum-free DMEM and cells were
treated with the respective test compounds dissolved in DMSO.
To account for potential unspecific effects of the solvent, the
final concentration of DMSO was always adjusted to 0.1%. One
hour after treatment the cells were stimulated with 2 ng/mL
human recombinant TNF-α for 6 h, and after a lysis step the
luminescence of the firefly luciferase and the fluorescence of
EGFP were quantified on a GeniosPro plate reader (Tecan;
Grödig, Austria). The luciferase signal derived from the NF-κB
reporter was normalized by the EGFP-derived fluorescence to
account for differences in cell number.
To estimate of cell viability one part of the experiments were
performed in cells that were not transfected with pEGFP-C1,
but instead stained for 1 h in serum-free medium supplemented
with 2 μM Cell Tracker Green CMFDA (C2925; Invitrogen) as
described [16]. Since this fluorescent probe is retained inside
living cells, it can be used to monitor cell membrane integrity
and thus has been broadly used to quantify viable cells [17-19].
For quantification of NF-κB activity in this experimental setting
the luciferase-derived signal from the NF-κB reporter was
normalized to the Cell Tracker Green CMFDA-derived
fluorescence to account for differences in cell number.
Potential differences in cell viability were monitored by
comparison of the Cell Tracker Green CMFDA fluorescence of
the solvent vehicle treated control cells and cells treated with
the indicated compounds.
Mice
C57BL/6J male, 8-9 weeks old mice were housed in
individually ventilated cages and fed with mouse chow and
acidified water ad libitum in the mouse facility of the Institute of
Vascular Biology and Thrombosis Research (Vienna, Austria).
Animal care and all experimental procedures were approved by
the Animal Experimental Committee of the Medical University
of Vienna and by the Austrian Ministry of Science (license no.
BMWF-66.009/0117-II/3b/2012).
Thioglycollate-induced peritonitis
The mice of the treatment groups – sterile thioglycollate and
perlatolic acid or thioglycollate alone - (3 animals per group)
were pre-treated i.p. with 1 mL of 6 µM perlatolic acid or 1 µL of
DMSO dissolved in 1 mL of saline. Thirty minutes later the
animals were injected i.p. with another 3 mL of saline with or
without sterile thioglycollate (4%), and containing again 2 μL
DMSO or perlatolic acid. Five hours after the second injection
mice were sacrificed by carbon dioxide exposure and
peritoneal cavities were washed three times with 2 mL of cold
PBS containing 3 mM EDTA and collected as intra-peritoneal
lavage. The leukocyte count in the peritoneum of untreated
control mice was assessed by lavage. Mice without
thioglycollate treatment were used as controls. The volume of
the collected lavage was measured and the cell count
determined by haemocytometer.
Statistical analysis
Data are expressed as mean ± S.E.. IC50 values were
calculated from averaged measurements at 3-5 different
concentrations of the compounds by nonlinear regression using
GraphPad Prism software (San Diego, CA) one site binding
competition. To calculate the IC50 values regarding NF-κB
inhibition at least three different concentrations measured in
quadruplicate in three independent transfection experiments
were used utilizing nonlinear regression with Data Analysis
Toolbox software (MDL Information System Inc., Nashville, TN,
USA). Statistical evaluation of the data was performed by one-
way ANOVA followed by a Bonferroni or Tukey-Kramer post-
hoc test for multiple comparisons respectively. A p value < 0.05
was considered statistically significant.
Results
Several Alpine lichen species were collected in Tyrol, South
Tyrol and Upper Austria. Seventeen species could be identified
unambiguously using morphological and microchemical
methods: Cetraria nivalis (L.) Ach., Cetraria pinastri (Scop.)
Gray, Cetrelia monachorum (Zahlbr.) W.L. Culb. & C.F. Culb.,
Cladonia carneola (Fr.) Fr., Lepraria incana (L.) Ach., Lobaria
linita (Ach.) Rabenh., Lobaria pulmonaria (L.) Hoffm.,
Nephroma resupinatum (L.) Ach., Parmelia caperata (L.) Ach.,
Parmeliopsis hyperopta (Ach.) Arnold, Peltigera leucophlebia
(Nyl.) Gyeln., Peltigera rufescens (Weiss) Humb., Platismatia
glauca (L.) W.L. Culb. & C.F. Culb., Stereocaulon alpinum
Laurer, Thamnolia vermicularis (Sw.) Ach. ex Schaer.,
Umbilicaria cyindrica (L.) Delise ex Duby, and Xanthoria
elegans (Link) Th. Fr. The ethanolic crude extracts of these
species (abbreviated with first letters of genus and epithet; CN,
CP, CM, CC, LI, LL, LP, NR, PC, PH, PL, PR, PG, SA, TV, UC,
XE, respectively) were tested for their potency to inhibit two
targets within eicosanoid biosynthesis, namely microsomal
prostaglandin E2 synthase-1 (mPGES-1) and 5-lipoxygenase
(5-LO), as well as NF-κB transactivation activity (Figure 2A -
D).
For all extracts, the inhibition of mPGES-1 was assessed at
concentrations of 3 and 30 µg/mL in a well-recognized cell-free
assay based on the enzymatic conversion of the substrate
PGH2 to PGE2 using the microsomal fraction of IL-1β-
stimulated A549 lung epithelial adenocarcinoma cells as
enzyme source [10]. The inhibition of 5-LO product formation
was analyzed in well-established cell-free and cell-based
assays [20] using puriﬁed human recombinant 5-LO and in
intact human PMNL, respectively, at 3 and 30 µg/mL. While the
cell-free assays allow analyzing a direct interaction with the
target enzymes at the molecular level, the cell-based test
system considers also regulatory aspects of 5-LO [20].
Furthermore, we screened the lichen extracts at 10 µg/mL for
their potential to inhibit NF-κB transactivation activity in TNF-α-
stimulated HEK-293 cells stably transfected with a NF-κB
luciferase reporter gene (HEK293/NF-κB-luc cells).
The ethanolic extracts of both Cetrelia monachorum (CM)
and Lepraria incana (LI) showed outstanding pharmacological
in vitro profiles in the applied assays (Figure 2A - D). For in
depth chemical investigations we finally selected CM, because
Anti-Inflammatory Depsides from C. monachorum
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Figure 2.  Effect of lichen crude extracts on mPGES-1 (A), purified 5-LO enzyme (B), 5-LO in PMNL (C) and NF-κB (D);
n=3-5.  
doi: 10.1371/journal.pone.0076929.g002
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of the problematic small amount of biomass available from the
powdery thallus of L. incana, a lichen species of the
Stereocaulaceae family, in contrast to the foliose character of
the thallus from C. monachorum , which belongs to the
Parmeliaceae family.
In fact, CM concentration-dependently inhibited PGE2
generation with a remarkably low IC50 of 2.0 µg/mL. In the two
5-LO assays (cell-free and cell-based), IC50 values of 1.4
µg/mL and 1.3 µg/mL, respectively, were determined for CM. In
TNF-α-stimulated HEK-293 cells CM inhibited the NF-κB
transactivation activity with an IC50 of 2.6 µg/mL thereby only
moderately affecting the viability of this cell line (measured
between 0.3 and 10 µg/mL; viability ≥ 75.05 ± 0.08 % at 10 µg/
mL).
The metabolite profile of CM was determined via HPLC-
DAD-ESI-MS analysis. Different chromatographic separation
steps succeeded in the isolation of three depsides (3 - 5) and
eight monoaromatic derivatives. By interpretation of mass
spectrometric and 1D and 2D NMR data the structures were
identified as ethyl haematommate (1),
methylbetaorcinolcarboxylate (2), atranorin (3), imbricaric acid
(4), perlatolic acid (5), 4-O-metylolivetolcarboxylic acid (6),
ethyl-4-O-methylolivetolcarboxylate (7), ethyl olivetolate (8),
olivetolmonomethylether (9), olivetol (10) and divarinol (11).
Their physical and spectroscopic properties are in accordance
with those reported previously ([21] and literature cited therein).
Except for 3 - 5, we identified the isolated compounds for the
first time from this lichen species.
The isolates of C. monachorum were investigated for their
potential to inhibit the activities of mPGES-1 and 5-LO. We
previously identified perlatolic acid (5) as a major mPGES-1
inhibitor by using a pharmacophore based virtual screening
(Bauer et al., 2012). Along these lines, we could identify this
compound as a major mPGES-1-inhibiting ingredient (IC50 =
0.4 µM) in CM. Additionally, two other depsides were analyzed,
namely atranorin (3) and imbricaric acid (4). As reported before
(Bauer et al., 2012), 3 did not affect the mPGES-1 activity,
whereas 4 exhibited a pronounced and concentration-
dependent inhibition in our experiments (IC50 = 1.9 µM, Figure
3), comparable to the synthetic mPGES-1 reference inhibitor
MK886 (IC50 = 2.3 µM, Figure 4) [22]. The monoaromatic
compounds (1, 2, and 6 - 11), however, did not suppress
enzyme activity up to a concentration of 10 µM.
Analysis of 5-LO inhibition by the 11 lichen compounds
revealed a significant inhibitory activity for the two depsides 4
and 5 in the cell-free assay with remarkable IC50 values of 3.5
µM and 0.4 µM, respectively. For comparison, the reference
drug zileuton (the only approved 5-LO inhibitor on the market)
revealed an IC50 = 0.7 µM (Figure 4), which is in agreement
with data from the literature (0.5 - 1 µM, [23]). Thus 4 and 5 act
as potent dual inhibitors of mPGES-1 and 5-LO, which implies
a favorable pharmacological profile [11]. In the cell-based
assay, 5-LO inhibition could be confirmed with a slightly lower
potency (IC50 = 5.3 µM and 1.8 µM, respectively). In parallel to
the results from the mPGES-1 evaluation, depside 3 and the
monoaromatic constituents (1, 2, and 6 - 11) did not affect 5-
LO activity up to 10 µM.
The three depsides (3 - 5) were additionally tested for their
potential to suppress NF-κB activation in TNF-α-stimulated
HEK-293/NF-κB-luc cells. In contrast to atranorin (3), imbricaric
acid (4) and perlatolic acid (5) showed pronounced and
concentration-dependent inhibition with IC50 values of 2.0 µM
and 7.0 µM, respectively (Figure 3). These activities presented
in Figure 3 are calculated after normalization of the NF-κB
activity to the fluorescence derived from the internal control
EGFP or from the cell viability dye Cell Tracker Green CMFDA,
which were used to assure that the observed effects are not
artifacts due to different cell number or differences in cell
viability, respectively.
Luciferase reporter gene expression reflects a downstream
event of the NF-κB signaling cascade and cannot provide
insights into the molecular targets contributing to the observed
NF-κB inhibition. Thus, we tested the active compounds 4 and
5 for their potential to suppress the activity of the inhibitor of
NF-κB kinase subunit beta (IKK2) as previously described [24],
since it is a prominent upstream target of the NF-κB signaling
cascade. However, the compounds did not inhibit IKK2 at a
concentration of up to 50 μM (data not shown). Accordingly,
this kinase is not a direct target of the NF-κB inhibiting
depsides 4 and 5.
Because 5 appeared the most potent anti-inflammatory
candidate based on the in vitro analysis, we aimed to assess
the inhibitory effect of 5 on inflammation in vivo. For this
purpose, we employed the thioglycollate (TG)-induced murine
peritonitis model [25]. Five hours after TG injection, we found a
more than fivefold increase in the total leukocyte count in the
peritoneal lavage fluid in the thioglycollate-treated animals. In
perlatolic acid (5) co-administered animals this inflammatory
response was significantly reduced by 30-40% (p< 0.05, Figure
5). Brandao and coworkers recently attested perlatolic acid (5)
a moderate selective cytotoxicity on UACC-62 and B16-F10
melanoma cells [26]. In the murine in vivo model of acute
inflammation performed in this study no hints of toxic effects
such as signs of serious discomfort or distress, change in
animal behaviour or mobility, increased breathing, elevated
temperature or nasal discharge were observed.
Since 4 and 5 were disclosed as those constituents
prominently contributing to the observed multi-potent effect of
CM, their contents were quantified by HPLC-DAD analysis in
the extract and determined to be 15.22% and 9.10%,
respectively. Considering the contents of 4 and 5, and
correlating their inhibitory effects with the measured
bioactivities of the parent extract, the mPGES-1 inhibitory
effectiveness of 4 and 5 are in full agreement with the original
extract, assuming these depsides to be the major ingredients
contributing to the suppression of PGE2 formation.
Recalculations for the inhibitory activities on 5-LO and NF-κB
attested CM more pronounced activities than can be achieved
simply by considering the bioactivities of 4 and 5, which leads
to the assumption of further minor constituents enhancing the
inhibitory effects or a synergistic action between the bioactive
depsides.
Anti-Inflammatory Depsides from C. monachorum
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Discussion
In this study, we identified C. monachorum as an Alpine
lichen species with pronounced inhibitory activity against three
major pro-inflammatory targets, namely mPGES-1, 5-LO and
NF-κB. To our best knowledge, no other plant- or natural
product-derived extract has been reported with such strong
mPGES-1-inhibitory activity, and also among 5-LO-suppressing
plant extracts [27], CM belongs to the most potent candidates.
Phytochemical characterization of the secondary metabolite
profile of CM and isolation of its constituents allowed the
identification of the main active ingredients of this lichen
extract, namely imbricaric acid (4) and perlatolic acid (5), which
both potently interfere with all three targets.
Based on these properties, C. monachorum represents a
valuable source for novel bioactive ingredients with high
Figure 3.  IC50 values of the isolated lichen compounds (1 - 11) in mPGES-1, 5-LO and NF-κB assays (n=3).  * n.d., not
determined; ** >10, significant inhibition at 10 µM; *** >>10, no significant inhibition at 10 µM.
doi: 10.1371/journal.pone.0076929.g003
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potential for pharmacological intervention with inflammatory
disorders.
Efficient inhibition of mPGES-1 by the isolated depsides (3 -
5) is in line with the SARs, which we previously established by
means of structural insights from pharmacophore-based ligand-
target interactions [8]. In that study, structural investigations
disclosed functional interaction sites of mPGES-1 crucial for
the inhibitory properties of ligands that approved n-pentyl side
chains of depsides as important feature for interference.
Underpinning this hypothesis, we determined in the present
study a slightly weaker effect for the newly identified imbricaric
acid (4) which is characterized by a three carbon chain
Figure 4.  IC50 values of positive controls in mPGES-1, 5-LO and NF-κB assays (n=3).  * n.d., not determined.
doi: 10.1371/journal.pone.0076929.g004
Figure 5.  Perlatolic acid (5) inhibits leukocyte recruitment in thioglycollate-induced peritonitis mouse model.  Box and
whisker plots represent median, lowest and highest detected values (n=3; **p<0.001, *p<0.05; ANOVA/Tukey).
doi: 10.1371/journal.pone.0076929.g005
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substitution at C6’ in contrast to 5 that carries the n-pentyl
residue. Atranorin (3) missing a mandatory free carboxylic acid
group completely loses any mPGES-1inhibitory activity but is
recognized to be the main active compound in a traditional
lichen preparation, inhibiting COX-1 and COX-2 in a 45% range
at 45 µM [28].
Here, we show for the first time that ingredients of C.
monachorum also inhibit 5-LO and NF-κB and these properties
might contribute to the overall anti-inflammatory activity of the
CM extract. Among the 11 secondary metabolites identified,
the diaromatic polyphenols (3 - 5) were revealed as the main
bioactive chemical class of this extract. The order of their
inhibitory activities in CM on both targets within eicosanoid
biosynthesis is 5 > 4 >>3, indicating that the potencies against
mPGES-1 and 5-LO run in parallel as potent dual inhibitors of
these enzymes.
Interestingly, perlatolic acid (5), with the low IC50 value of 0.4
µM for both 5-LO and mPGES-1, is even more potent as
compared to the reference inhibitors MK886 (of mPGES-1) and
zileuton (of 5-LO) in the applied assays. Such high potency,
together with the dual functionality against 5-LO and
mPGES-1, qualifies 5 as valuable pharmacological agent. Note
that under the assay conditions chosen, effects of the
compounds on transcription and translation of 5-LO can be
excluded due to the short incubation period (15 min).
Whereas atranorin (3) was found to be inactive against 5-LO
before [29], baeomycesic acid, a depside structurally closely
related to atranorin and distinguished by a free carboxylic acid
group, has been previously described as 5-LO inhibitor with
IC50 = 8.3 µM [30], assuming this structural feature as crucial
for activity. Furthermore, it was shown previously that the
depsidone lobaric acid exhibits 5-LO as well as 12-LO inhibiting
properties albeit with lower potencies (IC50 ≥ 28.5 µM; [4]).
Inhibition of NF-κB transactivation activity by depsides
described here is unprecedented. NF-κB inhibition has been
reported only for some lichen constituents from other chemical
classes, e.g. triterpenes [31], dibenzofurans [32], but to the
best of our knowledge, this is the first report of depsides
interacting with this pathway. Both, 4 and 5 exhibited a
pronounced suppression of NF-κB activation in the low
micromolar range, with imbricaric acid (4) being the most
potent inhibitor (IC50 2.0 µM) followed by perlatolic acid (5, IC50
7.0 µM); 3 only showed a moderate activity with an IC50 of 20
µM. Taking into account that IKK2 inhibition can be ruled out as
molecular mechanism for the observed NF-κB inhibition by 4
and 5, the underlying mode of NF-κB suppression still needs to
be elucidated.
By conducting a pilot study, we here show (Figure 5) that
one of the identified substances with anti-inflammatory activity
in in vitro assays, perlatolic acid (5), inhibits the inflammatory
recruitment of leukocytes in a peritonitis model in vivo. This
observed inhibition of leukocyte recruitment compares well with
the reported inhibition of recruitment by other inhibitors of the
NF-κB- [33] and 5-LO- signaling pathways [34] and with the
suggestion that mPGES-1 might be a likely candidate for a role
as PCAM-1 independent modulator of leukocyte recruitment
[35]. More detailed future analysis of the bioactive depsides in
diverse animal models of inflammation e.g. peritonitis
addressing various relevant biomarkers including cytokines,
chemokines and lipid mediators including PGs and LTs are
planned to fully assess the in vivo anti-inflammatory potential.
Correlation of the contents of these most abundant
constituents with 15.22% of 4 and 9.10% of 5 in CM underpins
the potent activities of the extract, which in this study could to
be streamlined to these two multi-targeting depsides.
Intriguingly, they bundle the inhibitory in vitro potential of three
prominent targets involved in inflammatory processes and,
thus, warrant further preclinical analysis as multi-target anti-
inflammatory leads.
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